Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Immix Biopharma, Inc. (IMMX)

Immix Biopharma reports 89% complete response rate in NEXICART-2 AL Amyloidosis trial

Positive Impact 4 of 5 product/contract Written later

Immix Biopharma said an interim update from its Phase 2 NEXICART-2 trial shows an 89% (40/45) complete response rate across all 45 enrolled relapsed/refractory AL Amyloidosis patients, as assessed by an independent review committee. The company said the final readout and BLA submission are planned for mid-2027, so the data remain interim and the therapy has not been approved.

Key points

  • Complete response rate of 89% (40/45) across all 45 enrolled patients, per an independent review committee
  • All 25 new patients are in complete response or MRD-negative (21 in CR, 4 MRD-negative)
  • Four MRD-negative patients still pending; the company says this could raise the CR rate to up to 98% (44/45)
  • Final readout and BLA submission planned for mid-2027; company reported no neurotoxicity or enterocolitis to date

The filing

CompanyImmix Biopharma, Inc. (IMMX)
Form8-K, current report
Filed with the SECSep 29, 2026, 7:00 AM ET
Accession number0001493152-26-044761

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.